DNASTAR Releases Lasergene 13 Software to Enhance RNA Research
Product News Mar 03, 2016
DNASTAR announced the release of Lasergene 13, which significantly advances scientists’ ability to perform RNA research on model and non-model organisms on standard desktop computers. Significant software enhancements include the ability to perform de novo transcriptome assembly of RNA data for any size project on a desktop computer, automatic mRNA annotation from one or more RefSeq databases selected by the researcher, creation of one or more transcript templates for gene expression analyses, and a complete RNA-Seq gene expression workflow, including strong visualization and analysis capability.
In addition, Lasergene 13 offers improved capabilities for scientists using other types of data, including access to a human Variant Annotation Database to support functional analysis of mutations, automated annotation mapping between microbial genomes, and enhanced template searching capabilities in support of NovaFold, the company’s protein structure prediction application.
Tom Schwei, Vice President and General Manager of DNASTAR, commented, “Lasergene 13 truly has something for everybody. In designing this release, we wanted to ensure we supported our Next-Generation Sequencing customers, who continue to explore new domains in their research.
With the recent growth in RNA-based sequencing, we decided to put a strong emphasis on RNA into Lasergene 13. We also wanted to ensure we supported human clinical researchers with advanced capability. Finally, we included in Lasergene 13 improvements that will appeal to scientists who work with bacteria and those who perform more traditional sequence analysis.
“Lasergene 13 helps scientists improve their research, regardless of the type of work they are doing, which is and has been our continuing goal as a company. We continue to take maximum advantage of our patented algorithms and unique best practices to solve some of the most difficult problems facing scientists and we look forward to continuing to do so in future Lasergene releases, as well.”